Pharma starting materials and intermediates: Production
How India is rebuilding plants it lost to China
What this tab covers Who makes it and how much: world capacity and output, utilisation, the top producing countries and companies globally and in India, concentration, new capacity coming, and each region's position.| Measure | Figure | Detail | Source |
|---|---|---|---|
| World capacity | not published globally; India PLI added about 56,800 t/yr by Dec 2025 | IndraStra citing PIB (June 2026) | |
| World output | not published | ||
| Capacity utilisation | not published | Chinese price cuts of 40-50% on some products after PLI launch and 30-45% higher Chinese import volumes have kept new Indian plants under pressure (IndraStra 2026). Lyfius sought anti-dumping protection in 2026. | IndraStra (June 2026); DGTR initiation (Sept 2026) |
| Concentration | China dominant; no public company shares | Some KSMs have only one or two producers worldwide. | qualitative |
| New capacity | PLI: 48 projects approved, about 56,800 t/yr commissioned by Dec 2025 | Bulk drug parks at Nakkapalli (Andhra Pradesh), Jambusar (Gujarat) and Una (Himachal Pradesh) are under development with common utilities (Business Today, July 2025; locations indicative). | IndraStra (2026); Business Today (2025) |
Top producing countries
- China: about 70% of India's critical bulk drug inputs; dominant world supplier
- India: growing via PLI; strong in some intermediates
- European Union: specialty and regulated KSMs; 6-APA from the EU covered by India's 2026 anti-dumping probe
Largest producers: global
| Company | Country | Volume | Year | Source |
|---|---|---|---|---|
| United Laboratories volumes not published | China | not published | 2025 | Gelonghui 6-APA market summary |
| Kelun Industry Group | China | not published | 2025 | Gelonghui |
| Centrient Pharmaceuticals former DSM Sinochem; enzymatic beta-lactams | Netherlands | 206 t/yr atorvastatin API (India PLI) | 2026 | PSU Watch |
| WuXi AppTec (WuXi STA) | China | not published | 2025 | GEN 2026 |
Largest producers: India
| Company | Country | Volume | Year | Source |
|---|---|---|---|---|
| Lyfius Pharma (Aurobindo) Rs 2,270 crore PLI investment | India | 15,000 t/yr penicillin G | 2024 | PSU Watch (2026) |
| Meghmani LLP Rs 60 crore PLI investment | India | 13,500 t/yr para-aminophenol | 2026 | PSU Watch (2026) |
| Kinvan (DPB group) cumulative production Rs 413 crore | India | 400 t/yr clavulanic acid | 2026 | PSU Watch (2026) |
| Andhra Organics (Virchow) Rs 151 crore investment | India | not published | 2026 | PSU Watch (2026) |
| Divi's Laboratories Kakinada Unit 3 backward integration | India | not published | FY26 | BoB Capital (May 2026) |
India makes many intermediates but relies on China for most fermentation KSMs and many bulk chemical KSMs. PLI cumulative sales were Rs 3,792 crore by June 2026, including Rs 560 crore exports (PSU Watch).
Position by region
| Region | Position |
|---|---|
| US | Indirect: Indian generics using Chinese KSMs supply about 40% of US generic prescriptions (indicative). |
| EU | Similar indirect exposure; 6-APA exporter. |
| India | Highest exposure; PLI, MIP and anti-dumping in play. |
| China | Main supplier; pricing power. |
| Japan | Imports KSMs from China. |
| Middle East | Not material. |